Checkpoint Therapeutics Statistics
Share Statistics
Checkpoint Therapeutics has 86.32M
shares outstanding. The number of shares has increased by 33.15%
in one year.
| Shares Outstanding | 86.32M |
| Shares Change (YoY) | 33.15% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | 25.62% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 158 |
| FTD / Avg. Volume | 0.01% |
Short Selling Information
The latest short interest is 3.8M, so 4.36% of the outstanding
shares have been sold short.
| Short Interest | 3.8M |
| Short % of Shares Out | 4.36% |
| Short % of Float | 4.72% |
| Short Ratio (days to cover) | 3.61 |
Valuation Ratios
The PE ratio is -2.26 and the forward
PE ratio is 4.51.
Checkpoint Therapeutics's PEG ratio is
0.05.
| PE Ratio | -2.26 |
| Forward PE | 4.51 |
| PS Ratio | 3096.54 |
| Forward PS | 0.7 |
| PB Ratio | -10.06 |
| P/FCF Ratio | -4.08 |
| PEG Ratio | 0.05 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for Checkpoint Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.37,
with a Debt / Equity ratio of 0.
| Current Ratio | 0.37 |
| Quick Ratio | 0.37 |
| Debt / Equity | 0 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $1,708.33 |
| Profits Per Employee | $-2,343,333.33 |
| Employee Count | 24 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by 155.21% in the
last 52 weeks. The beta is 1.19, so Checkpoint Therapeutics's
price volatility has been higher than the market average.
| Beta | 1.19 |
| 52-Week Price Change | 155.21% |
| 50-Day Moving Average | 3.96 |
| 200-Day Moving Average | 3.23 |
| Relative Strength Index (RSI) | 67.11 |
| Average Volume (20 Days) | 2,727,418 |
Income Statement
In the last 12 months, Checkpoint Therapeutics had revenue of 41K
and earned -56.24M
in profits. Earnings per share was -1.42.
| Revenue | 41K |
| Gross Profit | 41K |
| Operating Income | -56.17M |
| Net Income | -56.24M |
| EBITDA | -56.17M |
| EBIT | -56.17M |
| Earnings Per Share (EPS) | -1.42 |
Full Income StatementBalance Sheet
The company has 6.6M in cash and 0 in
debt, giving a net cash position of 6.6M.
| Cash & Cash Equivalents | 6.6M |
| Total Debt | n/a |
| Net Cash | n/a |
| Retained Earnings | -370.57M |
| Total Assets | 7.47M |
| Working Capital | -12.63M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -31.1M
and capital expenditures 0, giving a free cash flow of -31.1M.
| Operating Cash Flow | -31.1M |
| Capital Expenditures | n/a |
| Free Cash Flow | -31.1M |
| FCF Per Share | -0.78 |
Full Cash Flow StatementMargins
Gross margin is 100%, with operating and profit margins of -137009.76% and -137170.73%.
| Gross Margin | 100% |
| Operating Margin | -137009.76% |
| Pretax Margin | -137170.73% |
| Profit Margin | -137170.73% |
| EBITDA Margin | -137009.76% |
| EBIT Margin | -137009.76% |
| FCF Margin | -75856.1% |
